No, Genelux Corporation (NASDAQ: GNLX) does not pay a cash dividend to its shareholders. As a clinical-stage biotechnology enterprise focused heavily on research, development, and clinical trial advancement of its proprietary oncolytic viral immunotherapies, the company reinvests all of its available capital and financial resources back into core operational pipelines, laboratory testing, and drug development rather than distributing corporate earnings to investors.